Radisa Pavlovic

Radisa Pavlovic

Auto-generated profile, based on publicly available information

Radisa Pavlovic

Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2015 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
IPIvana Projovic
Ivana Projovic
DVDubravka Vukadinovic
Dubravka Vukadinovic
OKOlivera Zoran Kostic
Olivera Zoran Kostic
MJMilena Jurisevic
Milena Jurisevic
RPRadisa Pavlovic
Radisa Pavlovic
SSSrdjan Stefanovic
Srdjan Stefanovic

18 March 2023 in Medicina
Verified
Journal Article
Open access
PDF file
MJMarija Jovičić
Marija Jovičić
Miloš MilosavljevićMiloš Milosavljević
Miloš Milosavljević
MFMarko Folic
Marko Folic
RPRadiša Pavlović
Radiša Pavlović
SJSlobodan Janković
Slobodan Janković
Background and Objectives: Early neonatal sepsis is associated with a significant mortality rate despite modern treatment strategies. Our aim was to identify risk factors contributing to the occurrence of death in newborns with early neonatal sepsis. Materials and Methods: We conducted a retrospective cross-sectional study that included newborns with early sepsis who received care in the intensive and semi-intensive care units at the Institute of Neonatology, Belgrade, Serbia. Newborns with early neonatal sepsis who died comprised the case group, whereas those who survived made up the control group. The diagnostic and therapeutic approach to the septic condition was carried out independently of this study, according to valid hospital protocols and current good practice guidelines. The influence of a large number of variables on the examined dichotomous outcome, as well as the mutual interaction of potential predictor variables, was examined by binary logistic regression. Results: The study included 133 pregnant women and 136 newborns with early neonatal sepsis, of which 51 (37.5%) died, while the remaining 85 newborns (62.5%) survived. Newborns who died had a statistically significantly lower birth weight compared to those who survived (882.8 ± 372.2 g vs. 1660.9 ± 721.1 g, p = 0.000). Additionally, compared to newborns who survived, among the deceased neonates there was a significantly higher proportion of extremely preterm newborns (74.5% vs. 22.4%, p = 0.000). The following risk factors for the occurrence of death in early neonatal sepsis were identified: low birth weight, sepsis caused by gram-negative bacteria, and the use of double-inotropic therapy and erythrocyte transfusion during the first week. Conclusions: Pediatricians should pay special attention to infants with early neonatal sepsis in whom any of the identified risk factors are present in order to prevent a fatal outcome.

14 April 2018 in Indian Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
DSDragana Savić
Dragana Savić
ASAleksandra Simovic
Aleksandra Simovic
SMSlavica Marković
Slavica Marković
GKGordana Kostić
Gordana Kostić
BVBiljana Vuletić
Biljana Vuletić
RPRadisa Pavlović
Radisa Pavlović

1 January 2017 in Vojnosanitetski Pregled
Verified
Journal Article
Open access
DVDubravka Vukadinovic
Dubravka Vukadinovic
NSNatalija Samardzic
Natalija Samardzic
SJSlobodan Janković
Slobodan Janković
MTMarijana Tomic-Smiljanic
Marijana Tomic-Smiljanic
RPRadisa Pavlovic
Radisa Pavlovic
SSSrdjan Stefanovic
Srdjan Stefanovic

1 January 2021 in Hospital Pharmacology - International Multidisciplinary Journal
Verified
Journal Article
Open access
PDF file
SJSlobodan Janković
Slobodan Janković
BJBiljana Popovska Jovičić
Biljana Popovska Jovičić
RPRadiša T. Pavlović
Radiša T. Pavlović
RZRadica Zivkovic Zaric
Radica Zivkovic Zaric
Introduction: Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) is a rare, severe, systemic, drug-induced hypersensitivity syndrome, the most frequently associated with anticonvulsants. Case Report: A 35-years-old woman with a history of depression and hypothyroidism developed fever 39.5°C, enlarged, painful neck and axillary lymph nodes, slight facial edema around the mouth, confluent maculopapular rash, and laboratory signs of hepatocellular injury, leukocytosis and lymphopenia, but with normal eosinophil count. The syndrome was evident two weeks after starting carbamazepine, and gradually decreased after withdrawal of this drug and introduction of corticosteroid therapy. Conclusion: If a patient is taking carbamazepine and develops skin rash as well as fever and swollen lymph nodes, the physician should always check for internal organ damage and possible DRESS syndrome.

1 March 2020 in Serbian Journal of Experimental and Clinical Research
Verified
Journal Article
Open access
PDF file
RPRadisa Pavlovic
Radisa Pavlovic
SSSvetlana Stojkov
Svetlana Stojkov
ZBZahida Binakaj
Zahida Binakaj
The main objective of this investigation was to determine and summarize the economic burden of severe COPD exacerbations that required hospitalization and the difference in the costs of treatment between patients with frequent (at least two exacerbations in one year) and infrequent exacerbation. Our results suggested that significantly more resources had to be spent to treat patients with at least two hospitalizations during the study related to the use of medications primarily affecting the respiratory system (corticosteroids, p = 0.013, theophylline, p = 0.007) and total hospital stay (31336.68 ± 19140 RSD/517.53 ± 316.1 EUR versus 23650.15 ± 14956.0 RSD/390.59 ± 247 EUR, p=0.002) compared to patients who stayed in a semi-intensive care unit (12875.35 ± 20742.54 RSD versus 4310.62 ± 9779.78 RSD/ 212.64 ± 342.57 EUR versus 71.19 ± 161.51 EUR, p=0.006). Based on the total number of days in the hospital, the costs of the drugs, the materials used and services provided, patients from the frequent exacerbation group had significantly higher costs (80034.1 ± 36823.7 RSD/1321.78 ± 608.15 EUR versus 69425.5 ± 34083.1 RSD/1146.58 ± 562.89 EUR) comparedthan patients in the infrequent exacerbation group (p=0.039). Our results indicate that significantly more funds will be spent treating the deterioration of patients who stay longer in the hospital or in the semi-intensive care unit. Their condition will require a significantly greater use of drugs that are primarily used to treat the respiratory system and, therefore, will utiliseutilize significantly more resources.